Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05184816 · ClinicalTrials.gov registry record · Phase 1
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
A Phase 1 study of Leptomeningeal Metastases, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 7
- Study locations
NCT05184816 is a Phase 1 study of Leptomeningeal Metastases that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 35 participants, below the 54-participant average among 3 other Leptomeningeal Metastases trials with a reported enrollment target (35% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT05184816, a Phase 1 study of Leptomeningeal Metastases, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to find out whether deferoxamine (DFO) given intrathecally (directly into the CSF) is a safe treatment for people with leptomeningeal metastasis from solid tumor cancer. The researchers will test different doses of DFO to find the highest dose that causes few or mild side effects. When the dose is found, they will test it in future participants to see whether DFO is a safe and effective treatment for people with leptomeningeal metastasis from solid tumor malignancies. They are also doing this study to see how the body absorbs, distributes, gets rid of, and responds to DFO.
Conditions Studied
Interventions
- DRUG Deferoxamine (DFO)
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-12-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05184816
The ClinicalTrials.gov registry entry for NCT05184816 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 54-participant average among 3 other Leptomeningeal Metastases trials with a reported enrollment target (35% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leptomeningeal Metastases appearing as the primary indexed condition, and to 1 intervention - of which Deferoxamine (DFO) is the first listed.
NCT05184816 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05184816 about?
NCT05184816 is a clinical study titled "A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis". The researchers are doing this study to find out whether deferoxamine (DFO) given intrathecally (directly into the CSF) is a safe treatment for people with leptomeningeal metastasis from solid tumor cancer. The researchers will test different doses of DFO to find the highest dose that causes few or ...
What is the current status of trial NCT05184816?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2021-12-22. Estimated completion is 2026-12.
What conditions does trial NCT05184816 study?
This clinical trial studies the following conditions: Leptomeningeal Metastases.
What interventions are being tested in trial NCT05184816?
The interventions under investigation include: Deferoxamine (DFO) (DRUG).
Who is sponsoring clinical trial NCT05184816?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05184816 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leptomeningeal Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases
COMPLETED · Phase 1
-
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
COMPLETED · Phase 2
-
Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.